Acutaas Chemicals has inaugurated a semiconductor materials manufacturing plant in Gongju, South Korea, through its step-down subsidiary Indichem Inc. The facility was commissioned on August 28, 2026, marking the operational start of the company’s expansion into high-purity chemical supplies for the semiconductor industry.

The plant was completed within 11 months of its groundbreaking on September 29, 2025. It spans 16,513.7 square metres across three buildings: a main production block, a combined headquarters, research and development centre and pilot plant, and a warehouse. Additional land is available on-site for future expansion.

Joint Venture Structure

Indichem Inc. is a joint venture between Acutaas Advance Material Limited (AAML), a wholly owned subsidiary of Acutaas Chemicals, and J & Materials Co. Ltd of South Korea. AAML holds a 75% stake in the venture, while J & Materials holds the remaining 25%. Acutaas has invested KRW 30 billion (approximately ₹200 crore) in Indichem.

Operational Model

The venture operates on a synergistic two-country model. Chemicals are synthesised in India and then refined, tested and qualified to semiconductor grade in South Korea. This approach places the final production stage close to the customer base in the Republic of Korea, aiming to create operational and technological synergies. The materials produced require parts-per-billion purity levels, necessitating rigorous quality control and technical expertise.

Naresh Patel, Chairman and Managing Director of Acutaas Chemicals, stated that the rapid commissioning reflects the discipline of both partners. He noted that combining India’s strength in complex chemical synthesis with Korea’s expertise in ultra-high-purity refining creates a model neither company could have executed alone.

Jay Han, Chief Executive Officer of Indichem Inc., described the facility as a starting point for creating one of the leading semiconductor materials companies in the Republic of Korea. He emphasised that the strategy involves bringing Indian synthesis capabilities to Korea rather than asking customers to source from India.

What the Numbers Show

The investment structure highlights a significant capital commitment by Acutaas to secure majority control in the joint venture. With a ₹200 crore investment for a 75% stake, the total implied valuation of Indichem Inc. stands at approximately ₹266 crore. This capital allocation underscores the strategic priority placed on the semiconductor materials segment, which requires high initial capex for ultra-high-purity infrastructure before revenue generation begins.

Acutaas Chemicals received approval for an incentive package valued at ₹119.12 crore under the Electronics Components Manufacturing Scheme (ECMS). The approval was issued by Engineers India Limited, acting as Project Management Agency (PMA) on behalf of the Ministry of Electronics and Information Technology (MeitY). The scheme covers up to 25% of eligible investment on a total project investment of ₹256.47 crore for the electrolyte additives manufacturing business located at Jhagadia, Gujarat, over a benefit period extending to FY 2030-31. This is a government subsidy notification, not a commercial work order or sales contract.

Incentive structure

The key parameters of the ECMS approval are summarised below:

Order in financial context

This filing does not represent a confirmed revenue-generating order. As a result, it does not add to the company's order book or backlog. The total disclosed order book remains at zero, representing 0.00 quarters of average quarterly revenue coverage. The book-to-bill ratio is effectively non-existent as there is no active order inflow to compare against trailing twelve-month revenue of ₹1,489.3 crore. The ₹119.12 crore figure represents a potential reduction in net capital expenditure rather than a top-line revenue driver.

Company order track record

No previous order disclosures were found for Acutaas Chemicals in the last three fiscal quarters. The company operates in a sector where revenue is typically recognised through product sales rather than long-term project contracts, explaining the absence of traditional order book filings. Consequently, there is no historical order inflow data to benchmark against this incentive approval.

Execution and revenue quality

The company exhibits strong margin quality and consistent profitability. Operating profit margins expanded significantly, reaching 42.41% in Q4FY26 before settling at 34.30% in Q1FY27. Net profit generation remains robust, with ₹75.00 crore reported in the latest quarter.

Revenue growth

Acutaas Chemicals has sustained strong operational performance, with annual revenue growing from ₹1,023.80 crore in FY25 to ₹1,339.37 crore in FY26, representing YoY growth of +30.8% based on the latest annual data. This growth trajectory aligns with the company's expanding manufacturing capabilities, which are now further supported by the newly approved government incentives.

Working capital and execution capacity

The balance sheet is highly liquid with a current ratio of 3.82x, providing ample working capital buffer. Total liabilities/equity stands at a conservative 0.20x, indicating low leverage. Operating cashflow was ₹118.30 crore in FY25 against capex of ₹194.60 crore, resulting in negative free cashflow of ₹76.30 crore. The ₹119.12 crore ECMS incentive will be critical in funding future capital expenditures without straining the cash conversion cycle.

What to watch

• Incentive disbursement: Monitor the actual disbursement schedule of the ECMS funds. These are typically released in tranches linked to eligible investment milestones, not upfront.
• Capex execution: Track whether the Jhagadia facility expansion proceeds as planned. The incentive is tied to specific investment thresholds that must be met to unlock the full benefit.
• Margin sustainability: Watch if the high OPM levels (>34%) can be maintained as new capacity comes online and potentially faces pricing pressure.
• Cash flow conversion: Given the history of negative free cashflow, observe if the subsidy helps turn free cashflow positive in upcoming quarters.

Key observations

• Incentive vs order: This filing is a government subsidy approval, not a commercial order. It reduces net capex but does not generate direct revenue or add to the order book.
• Valuation check (as of August 18, 2026): P/E of 67.7x against ROCE of 16.51%. Valuation was pricing in execution improvement not yet visible in return ratios. (P/E is price-derived and will change; ROCE is from audited financials)
• Cash conversion: Operating cashflow of ₹118.30 crore in FY25 was insufficient to cover capex of ₹194.60 crore, resulting in negative free cashflow. The new incentive may alleviate this pressure.